ReviewAesthetic plastic surgery2026
Minimally Invasive Aesthetic Treatments for the Corrective Patient Archetype: Transforming Lives.
Review in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe definition of health encompasses mental, emotional, and social well-being, rather than simply the absence of disease. As a result, corrective aesthetic treatments are increasingly being viewed as an integral component of overall health rather than confined solely to the domain of aesthetics. In the realm of facial aesthetics, the corrective patient archetype is distinctly focused on rebalancing or proportioning facial features to improve confidence and self-perception. Minimally invasive treatments, such as botulinum toxin and hyaluronic acid (HA) gels, are known for their efficacy, tolerability, and ability to improve psychological and social outcomes. Additionally, hybrid injectables are gaining traction for their immediate filling and lifting effects that also provide biostimulating effects over time in the injected area.
methodsHere, we present a clinical review of the literature, accompanied by examples that illustrate the practical application of onabotulinumtoxinA, HA gels, and hybrid injectables (HA and calcium hydroxyapatite; Allergan Aesthetics, an AbbVie Company) for patients seeking corrections, including facial asymmetries (e.g., facial paralysis and hemifacial microsomia), trauma, and scarring, emphasizing the importance of tailored approaches to achieve optimal outcomes. RESULTS AND
conclusionsOnabotulinumtoxinA, HA gels, and hybrid injectables were effective, tolerable, and enhanced patients' quality of life by addressing both aesthetic and functional concerns. Overall, further research is needed to refine these treatments and expand their applications in corrective aesthetic medicine. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.